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Autocrine activation of the complement receptors C3aR and CD46 by complement
activation components C3a and C3b produced through C3 cleavage by the protease
cathepsin L (CTSL) during T cell stimulation is a requirement for IFN-γ production
and Th1 induction in human CD4+ T cells. Thus, lack of autocrine CD46 activation,
such as in CD46-deficient patients, is associated with defective Th1 responses and
recurrent infections. We have identified LGMN [the gene coding for legumain, also
known as asparaginyl endopeptidase (AEP)] as one of the key genes induced by CD46
co-stimulation during human CD4+ T cell activation. AEP processes and activates a
range of proteins, among those α1-thymosin and CTSL, which both drive intrinsically
Th1 activity—but has so far not been described to be functionally active in human
T cells. Here we found that pharmacological inhibition of AEP during activation of
human CD4+ T cells reduced CTSL activation and the CTSL-mediated generation of
intracellular C3a. This translated into a specific reduction of IFN-γ production without
affecting cell proliferation or survival. In line with these findings, CD4+ T cells isolated
from Lgmn−/− mice also displayed a specific defect in IFN-γ secretion and Th1 induction.
Furthermore, we did not observe a role for AEP-driven autocrine α1-thymosin activation in
T cell-derived IFN-γ production. These data suggest that AEP is an “upstream” activator
of the CTSL-C3-IFN-γ axis in human CD4+ T cells and hence an important supporter of
human Th1 induction.
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INTRODUCTION
Liver-derived, serum-circulating complement is a critical part of innate immunity mediating
protection against invading pathogens. Proteolytic activation of the complement key components
C3 into C3a and C3b and C5 into C5a and C5b upon pathogen sensing in blood leads to
opsonization and removal of invading microbes, mobilization of innate immune cells, and
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induction of the general inflammatory response (1). However,
it is now also acknowledged that complement serves an
equally central role in the direct regulation of human CD4+
T cell responses: signals delivered by the human-specific
C3b-binding complement regulator/receptor CD46 (membrane
cofactor protein, MCP) and the C3a receptor (C3aR) are essential
for the induction of IFN-γ in human CD4+ T cells (2, 3).
Furthermore, together with IL-2, CD46 also mediates IL-10
co-expression in expanded Th1 cells and, via this, the switch
toward a (self) regulatory contraction phase (4) (Figure S1A).
Unexpectedly, CD46 and C3aR-mediated activation of T cells
is independent of liver-derived C3, but driven in an autocrine
fashion by the C3 activation fragments C3b and C3a generated
through cathepsin L (CTSL)-mediated cleavage of intracellular
C3 that shunts to the cell surface upon T cell receptor (TCR)
activation (4, 5). Thus, lack of autocrine CD46 activation, such
as in CD46-deficient patients, results in reduced Th1 responses
and recurrent infections (2), whilst uncontrolled autocrine C3
activation and dysregulated CD46 engagement contributes to
hyperactive Th1 responses in autoimmunity (4–6).
Importantly, as increased intracellular CTSL-driven C3
activation can be pharmacologically targeted by a cell-permeable
CTSL inhibitor leading to normalization of hyper-Th1 activity at
least in vitro (5), we aimed at better understanding the modes of
CTSL activation in T cells. When analyzing gene arrays derived
from resting or TCR andCD46 activated humanCD4+ T cells (7),
we noted that asparaginyl endopeptidase (AEP or legumain) was
strongly expressed in T cells and further augmented upon CD46
co-stimulation. AEP is an asparagine-specific cysteine protease
found in lysosomes and plays an important but non-exclusive
role in the first step of invariant chain of major histocompatibility
class II (MHC II) processing in antigen presenting cells (APC)
(8). AEP also processes and activates a range of additional
proteins. Among those are α1-thymosin and CTSL, which both
drive intrinsically Th1 activity (5, 9), and AEP-deficient mice
accordingly exhibit a defect in the maturation of catepsins B, H,
and L in kidney cells (10). However, so far, AEP activity has not
been described in human T cells.
Here we describe for the first time a role for AEP in human
CD4+ T cells and its specific requirement for normal Th1
induction.
MATERIALS AND METHODS
Healthy Donors
Blood samples were obtained with ethical approvals at King’s
College London (Wandsworth Research Ethics Committee,
REC# 09/H0803/154). CD4+ T cells were purified from buffy
coats (NHSBT, Tooting, UK) or blood samples from healthy
volunteers after informed consent.
Mice
Wild type and Lgmn−/−mice were generated by Drs. Thomas
Reinheckel and Colin Watts as previously described (11). All
animals were maintained in accredited BSL2 facilities at KCL
and experiments performed in compliance with animal study
proposals approved by KCL.
Antibodies, Proteins, and Inhibitors
For a list of antibodies, proteins and inhibitors utilized, see
Supplementary Materials.
T Cell Isolation and Activation
For a protocol of human and mouse CD4+ T cell isolation and
activation, see Supplementary Materials.
Cytokine Measurements
Cytokine secretion by human and mouse T cells was measured
using the human and mouse Th1/Th2/Th17 Cytokine Bead
Arrays (BD Biosciences, Oxford, UK) or the combined
Secretion Assays for human IFN-γ and IL-10 purchased from
Miltenyi Biotec (Bergisch Gladbach, Germany) according to the
manufacturers’ provided protocols.
Confocal Microscopy
For a detailed protocol on the confocal microscopy performed
here including the measurement of the Pearson’s Correlation
Coefficient, refer to Supplementary Materials.
Western Blotting
For a detailed protocol on the Western botting procedures and
analyses utilized, see Supplementary Materials.
Statistical Analyses
Statistical analyses were performed on GraphPad Prism 7 (La
Jolla, CA). Data are presented as mean ± SEM and compared
using paired t-tests or one-way ANOVA with a Tukey multiple
comparison post-hoc test, as appropriate. p < 0.05 denoted
statistical significance throughout.
RESULTS
AEP Is Required for Normal Th1 Induction
in Human and Mouse CD4+ T Cells
Gene expression analyses performed on resting and CD3+CD46-
activated human CD4+ T cells suggested the expression
modulation of the LGMN gene, encoding the endopeptidase AEP
(7). Indeed, resting CD4+ T cells contained high levels of AEP
protein in the cytoplasm and CD46-mediated co-stimulation
during TCR activation further increased AEP protein levels but
simultaneously induced the nuclear translocation of a proportion
of AEP (Figures 1A,B). CD3+CD46-activation of T cells is
a strong and specific inducer of human Th1 responses (2).
The addition of increasing doses of a specific AEP inhibitor
(12) during CD3+CD46 activation significantly reduced the
percentage of actively IFN-γ-secreting cells as well as their
switching into the IL-10-producing contracting phase in cultures
in a dose-dependent manner (Figure 1C and Figure S1B). The
observed reduction of IFN-γ and IL-10 secretion also in CD3 and
CD3+CD28-activated T cells upon AEP inhibition was expected,
as TCR stimulation and CD28-costimulation function upstream
of CD46 and trigger increased intracellular CTSL-mediated
C3b generation and “background” CD46 engagement (5). Of
note, neither cell proliferation, viability nor production of Th2
cytokines such as IL-4 were affected by AEP inhibition and Th17
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FIGURE 1 | AEP is required for normal IFN-γ production in human and mouse CD4+ T cells. (A,B) CD46 drives AEP expression and nuclear translocation. Human
CD4+ T cells were left non-activated (NA) or activated with the depicted antibody combinations and AEP expression assessed 36 h post activation by (Ai) FACS with
(Aii) statistical analyses and (Bi) Western blotting of the cytoplasmic and nuclear fractions with (Bii) respective statistical analyses of the signals by densitometry.
(Continued)
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FIGURE 1 | Shown are one representative FACS and two Western blot experiments of n = 3 using a different donor each time. (C) AEP inhibition suppresses human
Th1 induction. T cells were activated as described under “A” with or without 25 or 50µM of a specific AEP inhibitor and IFN-γ and IL-10 (co)secretion measured 36 h
post activation. (Ci) shows FACS data derived from a representative donor whilst (Cii) summarizes the analyses for the shown activation conditions of n = 6 donors.
(D) AEP inhibition does not affect cell proliferation. Cell trace violet-labeled CD4+ T cells were CD3+CD46-activated in the presence or absence of 50µM AEP
inhibitor and cell proliferation measured at 6 d post activation. (Di) Shows a representative FACS profile and (Dii) the accompanying statistical analysis from four
different experiments (n = 4). (E) AEP is also required for normal Th1 induction in mice. Naïve CD4+ T cells isolated from wild type (WT) or AEP-deficient (Lgmn−/−)
mice (n = 5) were activated for 6 days under Th1, Th2, or Th17 skewing conditions and the total numbers of IFN-γ (Th1), IL-4 (Th2), or IL-17-positive (Th17) cells
assessed by intracellular cytokine staining. The number of FoxP3-positive natural regulatory T cells (nTregs) was assessed in activated cell cultures without addition of
skewing cytokines/antibodies. Error bar graphs represent mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001; ns, not significant.
responses were only reduced significantly under the CD3+CD46
stimulation condition (Figure 1D and Figures S1B,C).
We confirmed a role for AEP in the production and secretion
of IFN-γ by CD4+ T cells also in mice. Importantly, mice
do not express CD46 on somatic tissue (13) and a functional
homologue that drives Th1 induction—as shown for CD46 in
human T cells—has so far not been identified in mouse T cells
(14). Thus, purified CD4+ T cells from either wild type (WT)
or AEP-deficient (Lgmn−/−) were activated under Th1, Th2, or
Th17-skewing conditions and the percentage of IFN-γ, IL-4, and
IL-17-positive cells, as well as secretion of these cytokines into
culture media assessed. AEP deficiency was accompanied by a
specific and significant reduction in Th1 induction (Figure 1E).
We also observed an increase in the circulating natural FoxP3+
regulatory T cell (Treg) pool in Lgmn−/− animals (Figure 1E and
Figure S1D).
These data indicate that AEP activity is required for normal
Th1 induction in mice and men.
AEP Is Required for CTSL-Mediated C3
Activation in Human CD4+ T Cells
In human CD4+ T cells, CTSL is key in activating C3 and
thereby providing the ligands for autocrine CD46 and C3aR
activation needed for Th1 induction (5) (Figure S2A). CTSL
is usually synthesized as inactive pre-proenzyme and requires
proteolytic activation (first removal of the pre-peptide and
then processing into active single or double-chain forms) by
other proteases (Figure S2B) (15). AEP has been shown to
be involved in the processing of single-chain CTSL into the
double-chain form in mice (10, 16). Inhibition of AEP slightly
in resting cells but significantly during CD3+CD46 activation
reduced the generation of active single and double chain
CTSL forms as assessed by Western blotting and confocal
microscopy in human T cells (Figures 2A,B). Importantly,
the decrease in the generation of the CTSL active forms
by AEP inhibition led also to a proportional and significant
reduction in the activation of C3 as measured by the appearance
of the C3a neo-epitope in CD3+CD46-stimulated T cells
(Figures 2B,C and Figure S2C). A recent study found that
AEP cleaves FoxP3 in mouse induced regulatory T cells
and confirmed increased Tregs in Lgmn−/− mice (17). We
did, however, not observe changes in Foxp3 levels in resting
or activated human CD4+ T cells upon AEP inhibition
(Figure 2D).
AEP also processes pro-thymosin α into the active α1-
thymosin form (18) and α1-thymosin has been implicated
in human CD4+ T cell activation and modulation of
their cytokine production (19). However, the addition of
recombinant α1-thymosin during T cell activation in the
presence of the AEP inhibitor failed to rescue defective Th1
induction (Figure 2E). Human CD4+ T cells upregulate
major histocompatibility class II (MHC II) molecules (and
their maturation require CTSL cleavage) upon activation
(20)—however, this process also remained unaffected by AEP
inhibition (Figure S2D).
Together these data suggest that AEP activity in human CD4+
T cells drives Th1 induction via proteolytic activation of CTSL,
which in turn increases C3 activation and autocrine CD46 and
C3aR activation.
DISCUSSION
CTSL-mediated activation of intracellular C3 into C3a and C3b—
which then drive the autocrine engagement of the C3aR and
CD46, respectively—is critical to normal Th1 cell responses.
CD46 deficiency is accompanied hence by recurrent infections
throughout life and patients with serum C3 deficiency have
recurrent infections early in life. Of note, whilst C3 deficiency was
long thought to be based solely on reduced pathogen lytic activity
and impairment of innate immunity, it is now understood
that C3-deficiency indeed also impairs adaptive immunity (21).
Increased CTSL-mediated C3 activation, on the other hand,
drives Th1 hyper-activity in rheumatoid arthritis and in systemic
lupus erythematosus (5, 22). Pharmacological inhibition of
intracellular CTSL activity can normalize dysregulated Th1
responses, demonstrating that this pathway is therapeutically
amendable. Thus, understanding how CTSL activity is regulated
adds to our better understanding of Th1 biology and may also
provide additional needed therapeutic targets to control aberrant
Th1 immunity.
Here we identified AEP as an enzyme that processes CTSL
into its active forms in human CD4+ T cells. Inhibition of AEP
activity reduced the appearance of the CTSL active forms, the
generation of C3a in T cells and the induction of IFN-γ-secreting
cells by about 50%. This strongly suggests that AEP functions
upstream of the CTSL-C3 axis and is an integral part of human
Th1 initiation. AEP processes only the CTSL single chain into
the double chain form in mouse kidney cells (10). It is currently
unclear whether CTSL single chain-generating activity of AEP is
human (T cell) specific and/or if there is a difference in the CTSL
single vs. double chain forms’ ability or potency to cleave C3. The
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FIGURE 2 | AEP activity drives cathepsin L-mediated C3 activation in human CD4+ T cells. (A–C) AEP inhibition reduces the generation of active cathepsin L (CTSL)
and CTSL-mediated C3a production. T cells were left resting (NA) or CD3+CD46-activated with or without 50µM AEP inhibitor for 36 h. Appearance of the CTSL
active single or double chains generated from cleavage of the proenzyme form was measured by (Ai) Western blotting with (Aii) appropriate densitometric analyses of
(Continued)
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FIGURE 2 | the percentage of active (<30 kDa size bands) vs. non-active (>30 kDa size bands) CTSL forms. (B) confocal microscopy (left panels). The generation of
CTSL-dependent intracellular C3a was measured by (B) confocal microscopy (right panels) and (Ci) FACS with subsequent (Cii) statistical analysis. Data shown in
“A–C” are derived from n = 4 healthy donors. (D) T cells were activated under the depicted conditions and Foxp3 protein expression measured at 36 h post activation
via FACS analysis. Shown is one representative experiment of two similarly performed. (E) Autocrine AEP-mediated α1-thymosin activation is not required for Th1
induction. T cells were activated as under “A” with the addition of 1µM α1-thymosin as indicated and (Di) IFN-γ and IL-10-producing cells enumerated and (Dii) IFN-γ
secretion measured 36 h post activation (n = 3). Error bar graphs represent mean ± SEM. *P < 0.05, **P < 0.01; ns, not significant.
latter is feasible since single chain and double chain CTSL can
indeed have distinct substrate specificities (23).
This is the first description of a role for AEP in human Th1
biology. A previous study identified a role for AEP, together
with the protease inhibitor SerpinB1, in the regulation of
CTSL in mouse CD4+ T cells (24). Interestingly though, AEP
blockage with an inhibitor (the authors did not utilize Lgmn−/−
animals) in presence of Serpinb1 deficiency negatively controlled
CTSL-mediated Th17 induction without affecting Th1 responses.
The difference in outcome may be due to additional, not yet
defined, functions of SerpinB in Th17 induction. Here, using
Lgmn−/− animals, we found that, similar to human CD4+ T
cells, mouse Th1 responses are reduced while Th17 responses
remain unaffected. Of note, although mouse Th1 induction
also requires intracellular C3 activation, CD4+ T cells from
Ctsl−/− mice produce normal IFN-γ levels (5), indicating that
C3 activation in mice can occur in a CTSL-independent fashion.
In line with this, C3a levels are unchanged in Lgmn−/− animals
(Figure S2E). Given these differences, it seems unlikely that
AEP regulates mouse Th1 induction via a similar CTSL-C3
axis.
Previous work also noted increased natural and induced
Tregs in Lgmn−/− mice in line with the observation that AEP
stabilizes regulatory T cells through nuclear Foxp3 cleavage
(17, 25). Although CD46-activation indeed induced the nuclear
translocation of both AEP and CTSL (Figure 1B and Figure S2F)
we did not observe an effect of AEP inhibition on Foxp3—
or other confirmed AEP/CTSL targets such as α1-thymosin or
MHC II—in human CD4+ T cells. It is possible that the AEP
inhibitor used here only affects certain AEP activities. Patients
with genetic AEP deficiency that could be of help to better
define AEP’s roles in humans have so far not been described
and we would therefore not exclude that AEP (and CTSL) serves
additional functions aside from C3 activation in supporting Th1
activation.
In sum, AEP activity is important to normal Th1 induction
in mice and men—the exact modes of action of AEP in these
cells, however, seem to be species-specific and require further
investigation.
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